Hemab chairman John Maraganore (Ryan Emberley/Getty Images for Klick Inc.)
Rare blood disorders biotech Hemab raises $135M, begins trek into clinic
Hemab Therapeutics, led by Alnylam vet Benny Sorensen and chaired by John Maraganore, has raised $135 million from a new crop of investors as it begins pushing its blood disorder programs into the clinic.
The raise gives Hemab a cash runway into 2025, and the biotech has a slate of goals it wants to check off before then, including having five clinical candidates by 2025. Maraganore said in an interview with Endpoints News that the biotech wants to be in Phase III trials by then as well.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
